NR3C2 and hypertensive disorder: Using the HDAC inhibitor, valproic acid (VPA), Dr. Lee further found that HDAC inhibition prevented the development of hypertension through attenuating transcriptional activity of mineralocorticoid receptor (MR) by increasing its acetylation [13].